about
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulabilityRed cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortalityPrevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VSoluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism.Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality.Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort StudyOral anticoagulation with rivaroxaban during pregnancy: a case reportPO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patientsInfluence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia AAtrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulationAssociation of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer
P50
Q33599937-F0B956FD-5664-4B37-B970-ACC24E6FFDBEQ34408343-682B9D17-B585-4091-A5FE-87A50D967ACFQ36239524-C0175EA3-661C-4CC2-B2B3-D656C1041534Q36558396-1DD9C096-77EE-41BB-B731-407925385584Q38554324-2666FEE7-65BE-4F56-AB46-88AC72DB3613Q38607054-1D1A71F6-5D7A-49D6-8E00-D48120019DEAQ41456560-178FBF90-FFEF-4125-A73A-30F74FCFEF0BQ45711211-1621D304-95B4-428B-815C-BBEF63F8EFF1Q51020546-7354CBA0-B5B6-41F2-BDAC-B5C41B010153Q51090194-537F0E9E-4545-48F1-8252-CFF3B12D1ED9Q64135005-E920FBA7-42A0-45C3-9E22-BA0E429BCF6CQ87432855-3B968C31-BC1F-41C3-8796-D2999124668CQ89401089-CBAFD3F3-5CD0-4853-AB8C-817708DD6F3EQ89774833-E4E6DE95-A436-48B9-B511-14A157B73830Q90784699-D60FCCB8-7E75-4F39-A5F5-5F9D005F2F14Q92107537-9B11EA32-9666-437A-B5D8-E9FC31034EFB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Oliver Königsbrügge
@ast
Oliver Königsbrügge
@en
Oliver Königsbrügge
@es
Oliver Königsbrügge
@nl
Oliver Königsbrügge
@sl
type
label
Oliver Königsbrügge
@ast
Oliver Königsbrügge
@en
Oliver Königsbrügge
@es
Oliver Königsbrügge
@nl
Oliver Königsbrügge
@sl
prefLabel
Oliver Königsbrügge
@ast
Oliver Königsbrügge
@en
Oliver Königsbrügge
@es
Oliver Königsbrügge
@nl
Oliver Königsbrügge
@sl
P106
P21
P31
P496
0000-0002-6183-3685